Doctors test supercharged immune cells against tough melanoma
NCT ID NCT05470283
Summary
This is a first-in-human study to test the safety and find the right dose of a new, personalized cell therapy called OBX-115, given with the drug acetazolamide. It is for adults whose metastatic melanoma has come back or stopped responding to standard immunotherapy. Researchers will take a patient's own tumor-fighting immune cells, engineer them in a lab to be more powerful, and then infuse them back into the patient.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.